Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council.

Strober B, van de Kerkhof PCM, Callis Duffin K, Poulin Y, Warren RB, de la Cruz C, van der Walt JM, Stolshek BS, Martin ML, de Carvalho AVE.

Am J Clin Dermatol. 2019 Jun 21. doi: 10.1007/s40257-019-00458-2. [Epub ahead of print]

PMID:
31228013
2.

North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management.

Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, Crowell K, Eisen DB, Gottlieb AB, Hamzavi I, Hazen PG, Jaleel T, Kimball AB, Kirby J, Lowes MA, Micheletti R, Miller A, Naik HB, Orgill D, Poulin Y.

J Am Acad Dermatol. 2019 Jul;81(1):76-90. doi: 10.1016/j.jaad.2019.02.067. Epub 2019 Mar 11.

PMID:
30872156
3.

North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.

Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, Crowell K, Eisen DB, Gottlieb AB, Hamzavi I, Hazen PG, Jaleel T, Kimball AB, Kirby J, Lowes MA, Micheletti R, Miller A, Naik HB, Orgill D, Poulin Y.

J Am Acad Dermatol. 2019 Jul;81(1):91-101. doi: 10.1016/j.jaad.2019.02.068. Epub 2019 Mar 11.

PMID:
30872149
4.

Checklist for the Systemic Treatment of Psoriasis Using Biologics: A Delphi Study.

Fahim C, Kim BW, Bourcier M, Glassman S, Gooderham M, Guenther L, Gulliver W, Lynde C, Poulin Y, Pratt M, Shear N, Vender R, Walsh S, Fahim S.

J Cutan Med Surg. 2019 May/Jun;23(3):282-288. doi: 10.1177/1203475419833605. Epub 2019 Mar 10.

PMID:
30854878
5.

A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis.

Simpson EL, Imafuku S, Poulin Y, Ungar B, Zhou L, Malik K, Wen HC, Xu H, Estrada YD, Peng X, Chen M, Shah N, Suarez-Farinas M, Pavel AB, Nograles K, Guttman-Yassky E.

J Invest Dermatol. 2019 May;139(5):1063-1072. doi: 10.1016/j.jid.2018.10.043. Epub 2018 Dec 5.

6.

Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section IV: Treatment Options for the Management of Atopic Dermatitis.

Dhadwal G, Albrecht L, Gniadecki R, Poulin Y, Yeung J, Hong CH, Gooderham MJ.

J Cutan Med Surg. 2018 Nov/Dec;22(1_suppl):21S-29S. doi: 10.1177/1203475418805721.

PMID:
30439301
7.

Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section V: Consensus Statements on the Assessment and Management of Adult Patients With Moderate-to-Severe Atopic Dermatitis.

Hong CH, Gooderham MJ, Albrecht L, Bissonnette R, Dhadwal G, Gniadecki R, Grewal P, Kirchhof MG, Landells I, Lansang P, Lynde CW, Papp KA, Poulin Y, Sussman G, Turchin I, Wiseman M, Yeung J.

J Cutan Med Surg. 2018 Nov/Dec;22(1_suppl):30S-35S. doi: 10.1177/1203475418803625.

PMID:
30439300
8.

Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document.

Gooderham MJ, Hong CH, Albrecht L, Bissonnette R, Dhadwal G, Gniadecki R, Grewal P, Kirchhof MG, Landells I, Lansang P, Lynde CW, Papp KA, Poulin Y, Sussman G, Turchin I, Wiseman M, Yeung J.

J Cutan Med Surg. 2018 Nov/Dec;22(1_suppl):3S-5S. doi: 10.1177/1203475418803627.

PMID:
30439298
9.

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.

Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H.

Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7.

PMID:
30097359
10.

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).

Gottlieb AB, Blauvelt A, Thaçi D, Leonardi CL, Poulin Y, Drew J, Peterson L, Arendt C, Burge D, Reich K.

J Am Acad Dermatol. 2018 Aug;79(2):302-314.e6. doi: 10.1016/j.jaad.2018.04.012. Epub 2018 Apr 13.

11.

OBSERVE-5: Comparison of Etanercept-Treated Psoriasis Patients From Canada and the United States.

Papp KA, Bourcier M, Poulin Y, Lynde CW, Gilbert M, Poulin-Costello M, Billen L, Isaila M.

J Cutan Med Surg. 2018 May/Jun;22(3):297-303. doi: 10.1177/1203475418755998. Epub 2018 Feb 22.

PMID:
29466863
12.

Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies.

Pariser D, Frankel E, Schlessinger J, Poulin Y, Vender R, Langley RG, Meng X, Guana A, Nyirady J.

Dermatol Ther (Heidelb). 2018 Mar;8(1):17-32. doi: 10.1007/s13555-017-0211-4. Epub 2017 Dec 7.

13.

Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition.

Bissonnette R, Bourcier M, Gooderham M, Hong CH, Landells I, Lynde C, Papp K, Poulin Y, Vender R, Wiseman MC.

J Cutan Med Surg. 2017 Sep/Oct;21(2_suppl):2S-40S. doi: 10.1177/1203475417722552. No abstract available.

PMID:
29156950
14.

A Treatment Algorithm for Moderate to Severe Atopic Dermatitis in Adults.

Lynde CW, Bourcier M, Gooderham M, Guenther L, Hong CH, Papp KA, Poulin Y, Sussman G, Vender R.

J Cutan Med Surg. 2018 Jan/Feb;22(1):78-83. doi: 10.1177/1203475417733460. Epub 2017 Oct 28. Review.

PMID:
29082775
15.

Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study.

Bissonnette R, Haydey R, Rosoph LA, Lynde CW, Bukhalo M, Fowler JF, Delorme I, Gagné-Henley A, Gooderham M, Poulin Y, Barber K, Jenkin P, Landells I, Pariser DM.

J Eur Acad Dermatol Venereol. 2018 Mar;32(3):403-410. doi: 10.1111/jdv.14647. Epub 2017 Nov 15.

PMID:
29055155
16.

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.

Elewski BE, Okun MM, Papp K, Baker CS, Crowley JJ, Guillet G, Sundaram M, Poulin Y, Gu Y, Geng Z, Williams DA, Rich PA.

J Am Acad Dermatol. 2018 Jan;78(1):90-99.e1. doi: 10.1016/j.jaad.2017.08.029. Epub 2017 Oct 6.

17.

An Open Letter to Health Canada.

Papp K, Albrecht L, Barber K, Bourcier M, Dion PL, Freiman A, Gooderham M, Guenther L, Gulliver W, Hong CH, Lynde C, Poulin Y, Siddha S, Toole J, Toth D, Vender R, Wasel N, Wiseman M.

J Cutan Med Surg. 2017 May/Jun;21(3):195-196. doi: 10.1177/1203475417704642. No abstract available.

PMID:
28903599
18.

Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials.

Paul C, Guenther L, Torii H, Sofen H, Burge R, Lin CY, Potts Bleakman A, Mallbris L, Poulin Y.

J Eur Acad Dermatol Venereol. 2018 Jan;32(1):68-72. doi: 10.1111/jdv.14581. Epub 2017 Oct 6.

PMID:
28881462
19.

Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome.

Lima H, Gooderham M, Dutz J, Lynde C, Chapdelaine H, Ellis A, Gilbert M, Ho V, Papp K, Poulin Y, Sussman G.

Allergy Asthma Clin Immunol. 2017 Aug 24;13:38. doi: 10.1186/s13223-017-0210-0. eCollection 2017.

20.

Approach to the Management of Patients With Hidradenitis Suppurativa: A Consensus Document.

Alavi A, Lynde C, Alhusayen R, Bourcier M, Delorme I, George R, Gooderham M, Gulliver W, Kalia S, Marcoux D, Poulin Y.

J Cutan Med Surg. 2017 Nov/Dec;21(6):513-524. doi: 10.1177/1203475417716117. Epub 2017 Jun 22. Review.

PMID:
28639459
21.

Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice.

Gladman DD, Poulin Y, Adams K, Bourcier M, Barac S, Barber K, Chandran V, Dutz J, Flanagan C, Gooderham MJ, Gulliver WP, Ho VC, Hong CH, Karsh J, Khraishi MM, Lynde CW, Papp KA, Rahman P, Rohekar S, Rosen CF, Russell AS, Vender RB, Yeung J, Ziouzina O, Zummer M.

J Rheumatol. 2017 Apr;44(4):519-534. doi: 10.3899/jrheum.161473.

PMID:
28604347
22.

Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients.

Masson Regnault M, Konstantinou MP, Khemis A, Poulin Y, Bourcier M, Amelot F, Bulaï Livideanu C, Paul C.

J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1491-1496. doi: 10.1111/jdv.14387. Epub 2017 Aug 8.

PMID:
28585707
23.

Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials.

Guenther L, Warren RB, Cather JC, Sofen H, Poulin Y, Lebwohl M, Terui T, Potts Bleakman A, Zhu B, Burge R, Reich K, van de Kerkhof P.

J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1867-1875. doi: 10.1111/jdv.14377. Epub 2017 Sep 4.

PMID:
28573743
24.

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.

Blauvelt A, Papp KA, Sofen H, Augustin M, Yosipovitch G, Katoh N, Mrowietz U, Ohtsuki M, Poulin Y, Shrom D, Burge R, See K, Mallbris L, Gordon KB.

J Eur Acad Dermatol Venereol. 2017 Jun;31(6):1004-1013. doi: 10.1111/jdv.14163. Epub 2017 Mar 31. Erratum in: J Eur Acad Dermatol Venereol. 2017 Oct;31(10 ):1764.

25.

Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study.

Bissonnette R, Poulin Y, Drew J, Hofland H, Tan J.

J Am Acad Dermatol. 2017 Jan;76(1):33-39. doi: 10.1016/j.jaad.2016.08.053. Epub 2016 Oct 28.

PMID:
28029390
26.

Definition of Moderate to Severe Hidradenitis Suppurativa: A Position Paper by the Canadian Hidradenitis Suppurativa Foundation (CHSF).

Alavi A, Adam DN, Alhusayen R, Boucier M, Brassard A, Coutts P, Gooderham M, Gulliver W, Hong CH, Lynde C, Marcoux D, Papp K, Poulin Y, Sibbald RG, Shear NH.

J Cutan Med Surg. 2016 Nov;20(6):613-615. No abstract available.

PMID:
27821541
27.

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.

Bissonnette R, Papp KA, Poulin Y, Gooderham M, Raman M, Mallbris L, Wang C, Purohit V, Mamolo C, Papacharalambous J, Ports WC.

Br J Dermatol. 2016 Nov;175(5):902-911. doi: 10.1111/bjd.14871. Epub 2016 Sep 24.

PMID:
27423107
28.

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators.

N Engl J Med. 2016 Dec 15;375(24):2335-2348. Epub 2016 Sep 30.

29.

Review of Systemic Treatment Options for Adult Atopic Dermatitis.

Gooderham M, Lynde CW, Papp K, Bourcier M, Guenther L, Gulliver W, Hong CH, Poulin Y, Sussman G, Vender R.

J Cutan Med Surg. 2017 Jan/Feb;21(1):31-39. doi: 10.1177/1203475416670364. Epub 2016 Sep 22. Review.

PMID:
27635033
30.

Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.

Thaçi D, Kimball A, Foley P, Poulin Y, Levi E, Chen R, Feldman SR.

J Eur Acad Dermatol Venereol. 2017 Mar;31(3):498-506. doi: 10.1111/jdv.13918. Epub 2016 Oct 10.

31.

Canadian Clinical Practice Guidelines for Rosacea.

Asai Y, Tan J, Baibergenova A, Barankin B, Cochrane CL, Humphrey S, Lynde CW, Marcoux D, Poulin Y, Rivers JK, Sapijaszko M, Sibbald RG, Toole J, Ulmer M, Zip C.

J Cutan Med Surg. 2016 Sep;20(5):432-45. doi: 10.1177/1203475416650427. Epub 2016 May 17. Review.

PMID:
27207355
32.

Management of acne: Canadian clinical practice guideline.

Asai Y, Baibergenova A, Dutil M, Humphrey S, Hull P, Lynde C, Poulin Y, Shear NH, Tan J, Toole J, Zip C.

CMAJ. 2016 Feb 2;188(2):118-126. doi: 10.1503/cmaj.140665. Epub 2015 Nov 16. No abstract available.

33.

Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0·015% gel: a randomized, controlled 12-month study.

Garbe C, Basset-Seguin N, Poulin Y, Larsson T, Østerdal ML, Venkata R, Lear JT.

Br J Dermatol. 2016 Mar;174(3):505-13. doi: 10.1111/bjd.14222. Epub 2016 Jan 9.

PMID:
26471889
34.

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).

Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB.

Br J Dermatol. 2015 Dec;173(6):1387-99. doi: 10.1111/bjd.14164. Epub 2015 Nov 7.

PMID:
26357944
35.

Mediastinal Abscess Following Endobronchial Ultrasound Transbronchial Needle Aspiration in a Patient With Sarcoidosis.

McGovern Murphy F, Grondin-Beaudoin B, Poulin Y, Boileau R, Dumoulin E.

J Bronchology Interv Pulmonol. 2015 Oct;22(4):370-2. doi: 10.1097/LBR.0000000000000183.

PMID:
26348695
36.

Right upper lobe lung cancer: Resection through left anterior mediastinotomy.

Sirois M, Abu Arab W, Turcotte E, Poulin Y.

Asian Cardiovasc Thorac Ann. 2016 Jan;24(1):92-4. doi: 10.1177/0218492315593696. Epub 2015 Jun 29.

PMID:
26124429
37.

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Kalb RE, Fiorentino DF, Lebwohl MG, Toole J, Poulin Y, Cohen AD, Goyal K, Fakharzadeh S, Calabro S, Chevrier M, Langholff W, You Y, Leonardi CL.

JAMA Dermatol. 2015 Sep;151(9):961-9. doi: 10.1001/jamadermatol.2015.0718.

PMID:
25970800
38.

Long-term Management of Moderate to Severe Plaque Psoriasis Patients With Etanercept: A Case Series.

Bourcier M, Papp KA, Gulliver WP, Poulin Y, Barber K, Poulin-Costello M, Shelton J.

J Cutan Med Surg. 2015 Nov-Dec;19(6):561-9. doi: 10.1177/1203475415584511. Epub 2015 May 7.

PMID:
25951825
39.

Non-melanoma Skin Cancer in Canada Chapter 3: Management of Actinic Keratoses.

Poulin Y, Lynde CW, Barber K, Vender R, Claveau J, Bourcier M, Ashkenas J; Canadian non-Melanoma Skin Cancer Guidelines Committee.

J Cutan Med Surg. 2015 May-Jun;19(3):227-38. doi: 10.1177/1203475415583414. Epub 2015 Apr 29. Erratum in: J Cutan Med Surg. 2015 Nov-Dec;19(6):604. J Cutan Med Surg. 2015 Nov-Dec;19(6):604.

PMID:
25926621
40.

Non-melanoma Skin Cancer in Canada Chapter 5: Management of Squamous Cell Carcinoma.

Sapijaszko M, Zloty D, Bourcier M, Poulin Y, Janiszewski P, Ashkenas J; Canadian Non-melanoma Skin Cancer Guidelines Committee.

J Cutan Med Surg. 2015 May-Jun;19(3):249-59. doi: 10.1177/1203475415582318. Epub 2015 Apr 28. Erratum in: J Cutan Med Surg. 2015 Nov-Dec;19(6):604. J Cutan Med Surg. 2015 Nov-Dec;19(6):604.

PMID:
25922470
41.

Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis.

Reich K, Papp KA, Matheson RT, Tu JH, Bissonnette R, Bourcier M, Gratton D, Kunynetz RA, Poulin Y, Rosoph LA, Stingl G, Bauer WM, Salter JM, Falk TM, Blödorn-Schlicht NA, Hueber W, Sommer U, Schumacher MM, Peters T, Kriehuber E, Lee DM, Wieczorek GA, Kolbinger F, Bleul CC.

Exp Dermatol. 2015 Jul;24(7):529-35. doi: 10.1111/exd.12710. Epub 2015 May 8.

42.

Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial.

Sigurgeirsson B, Boznanski A, Todd G, Vertruyen A, Schuttelaar ML, Zhu X, Schauer U, Qaqundah P, Poulin Y, Kristjansson S, von Berg A, Nieto A, Boguniewicz M, Paller AS, Dakovic R, Ring J, Luger T.

Pediatrics. 2015 Apr;135(4):597-606. doi: 10.1542/peds.2014-1990. Epub 2015 Mar 23.

43.

Think beyond the Skin: 2014 Canadian Expert Opinion Paper on Treating to Target in Plaque Psoriasis.

Gulliver W, Lynde C, Dutz JP, Vender RB, Yeung J, Bourcier M, Dion PL, Hong CH, Searles G, Poulin Y.

J Cutan Med Surg. 2015 Jan-Feb;19(1):22-7. doi: 10.2310/7750.2014.13151. Epub 2015 Jan 1.

PMID:
25775659
44.

The Relationship Between Dermatologist- and Patient-Reported Acne Severity Measures and Treatment Recommendations.

Tan J, Frey MP, Knezevic S, Poulin Y, Lynde CW, Gulliver WP, Gupta AK, Sebaldt RJ, Thomas DR, Sapra S.

J Cutan Med Surg. 2015 Sep-Oct;19(5):464-9. doi: 10.1177/1203475415576464. Epub 2015 Mar 11.

PMID:
25775621
45.

Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE.

Papp KA, Barber K, Bissonnette R, Bourcier M, Lynde CW, Poulin Y, Shelton J, Garces K, Toole J, Poulin-Costello M.

J Eur Acad Dermatol Venereol. 2015 Aug;29(8):1555-61. doi: 10.1111/jdv.12934. Epub 2015 Jan 21.

46.

Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up.

Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasfi Y, Chan D, Hsu MC, You Y, Poulin Y, Korman N, Prinz JC, Reich K; PHOENIX 2 Investigators.

Br J Dermatol. 2015;172(5):1371-83. doi: 10.1111/bjd.13469. Epub 2015 Mar 22.

47.

A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE).

Papp KA, Barber K, Bissonnette R, Bourcier M, Lynde CW, Poulin Y, Shelton J, Toole J, Vieira A, Poulin-Costello M.

J Eur Acad Dermatol Venereol. 2015 Feb;29(2):361-6. doi: 10.1111/jdv.12555. Epub 2014 Jul 1.

48.
49.

Interleukin 17A: toward a new understanding of psoriasis pathogenesis.

Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S.

J Am Acad Dermatol. 2014 Jul;71(1):141-50. doi: 10.1016/j.jaad.2013.12.036. Epub 2014 Mar 18. Review.

PMID:
24655820
50.

Psychometric properties of the French Female Sexual Function Index (FSFI).

Wylomanski S, Bouquin R, Philippe HJ, Poulin Y, Hanf M, Dréno B, Rouzier R, Quéreux G.

Qual Life Res. 2014 Sep;23(7):2079-87. doi: 10.1007/s11136-014-0652-5. Epub 2014 Mar 2.

PMID:
24585184

Supplemental Content

Loading ...
Support Center